A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal development factor receptor , offers been initiated by Abbott in the U.S. The trial will measure the security and pharmacokinetics of ABT-806 in individuals with advanced solid tumors likely or known to exhibit EGFR. A clinical study of the chimeric predecessor mAb, ch806, released in PNAS, suggested an capability to focus on and bind selectively to EGFR expressing tumors, with essentially no targeting of normal tissues. Preclinical data show that ABT-806 may be effective in treating multiple tumor types. ‘We are hopeful that ABT-806 will confirm the preclinical studies performed by Abbott and the Ludwig Institute in human beings. We anticipate further expanding our understanding of mAb 806 with this trial,’ noted James Fiore, CEO of LSP..Donegan. ‘We recommend these higher risk sufferers, in class 3 or 4 4, be carefully managed medically so that any existing conditions can be treated and any evolving medical problems can be addressed regularly,’ continued Dr. Donegan. Dr. Donegan added, ‘Utilizing strategies that improve bone health and prevent hip fractures are ways to limit the significant impact a fall can have.’ Prevent hip and additional bone fractures Falls are the number one reason behind hip fractures in elderly patients – and falls can be lethal for old adults.